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Abstract 
Sustained administration of opioid antagonists to rodents results in an 
enhanced antinociceptive response to agonists. We investigated the changes in 
spinal -opioid receptor signalling underlying this phenomenon. Rats received 
naltrexone (120 g/h; 7 days) via osmotic minipumps. The antinociceptive 
response to the -agonist sufentanil was tested 24 h after naltrexone 
withdrawal. In spinal cord samples, we determined the interaction of -receptors 
with G proteins (agonist-stimulated [35S]GTPS binding and 
immunoprecipitation of [35S]GTPS-labelled G subunits) as well as -opioid 
receptor-dependent inhibition of the adenylyl cyclase (AC) activity. Chronic 
naltrexone treatment augmented DAMGO-stimulated [35S]GTPS binding, 
potentiated the inhibitory effect of DAMGO on the AC/cAMP pathway, and 
increased the inverse agonist effect of naltrexone on cAMP accumulation. In 
control rats, the inhibitory effect of DAMGO on cAMP production was 
antagonized by pertussis toxin (PTX) whereas, after chronic naltrexone, the 
effect became resistant to the toxin, suggesting a coupling of -receptors to 
PTX-insensitive Gz subunits. Immunoprecipitation assays confirmed the 
transduction switch from Gi/o to Gz proteins. The consequence was an 
enhancement of the antinociceptive response to sufentanil that, in consonance 
with the neurochemical data, was prevented by Gαz antisense 
oligodeoxyribonucleotides but not by PTX. Such changes in opioid receptor 
signalling can be a double-edged sword. On the one hand, they may have 
potential applicability to the optimisation of the analgesic effects of opioid drugs 
for the control of pain. On the other hand, they represent an important 
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homeostatic dysregulation of the endogenous opioid system that might account 
for undesirable effects in patients chronically treated with opioid antagonists.  
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Abstract 1 
 Sustained administration of opioid antagonists to rodents results in an enhanced 2 
antinociceptive response to agonists. We investigated the changes in spinal -opioid 3 
receptor signalling underlying this phenomenon. Rats received naltrexone (120 g/h; 4 
7 days) via osmotic minipumps. The antinociceptive response to the -agonist 5 
sufentanil was tested 24 h after naltrexone withdrawal. In spinal cord samples, we 6 
determined the interaction of -receptors with G proteins (agonist-stimulated 7 
[35S]GTPS binding and immunoprecipitation of [35S]GTPS-labelled G subunits) as 8 
well as -opioid receptor-dependent inhibition of the adenylyl cyclase (AC) activity. 9 
Chronic naltrexone treatment augmented DAMGO-stimulated [35S]GTPS binding, 10 
potentiated the inhibitory effect of DAMGO on the AC/cAMP pathway, and increased 11 
the inverse agonist effect of naltrexone on cAMP accumulation. In control rats, the 12 
inhibitory effect of DAMGO on cAMP production was antagonized by pertussis toxin 13 
(PTX) whereas, after chronic naltrexone, the effect became resistant to the toxin, 14 
suggesting a coupling of -receptors to PTX-insensitive Gz subunits. 15 
Immunoprecipitation assays confirmed the transduction switch from Gi/o to Gz 16 
proteins. The consequence was an enhancement of the antinociceptive response to 17 
sufentanil that, in consonance with the neurochemical data, was prevented by Gαz 18 
antisense oligodeoxyribonucleotides but not by PTX. Such changes in opioid 19 
receptor signalling can be a double-edged sword. On the one hand, they may have 20 
potential applicability to the optimisation of the analgesic effects of opioid drugs for 21 
the control of pain. On the other hand, they represent an important homeostatic 22 
dysregulation of the endogenous opioid system that might account for undesirable 23 
effects in patients chronically treated with opioid antagonists.  24 
 3 
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Abbreviations: 5 
 6 
AC: Adenyly cyclase  7 
DAMGO: Tyr-D-Ala-Gly-Me-Fe-Gly-ol-enkephalin 8 
FK: Forskolin  9 
ODN: oligodeoxyribonucleotides 10 
PTX: Pertussis toxin 11 
 12 
13 
 4 
1. Introduction 1 
Opioid drugs produce their pharmacological effects by interacting with specific G-2 
protein–coupled receptors (namely -, - and -opioid receptors) (Snyder and 3 
Pasternak, 2003). The functional interaction of opioid receptors with the pertussis 4 
toxin (PTX)–sensitive Gαi1,2,3 and Gαo transducers as well as PTX-resistant Gαz has 5 
been clearly demonstrated in heterologous expression systems, neural cell lines and 6 
in the CNS (Chan et al., 1995; Chalecka-Franaszek et al., 2000; Tso and Wong, 7 
2000). In animal models, evidence that Gαi1,2,3, Gαo, Gαz and Gαq can contribute to µ-8 
opioid signalling and antinociception was provided by studies using PTX, specific 9 
antisera or antisense oligodeoxyribonucleotides against specific G-protein subunits 10 
and null transgenic mouse strains (Sánchez-Blázquez et al., 1995; Standifer et al., 11 
1996; Garzón et al., 1998; Sánchez-Blázquez et al., 2001; Hendry et al., 2000; Yang 12 
et al., 2000; Yoburn et al., 2003; Mostany et al., 2008; Lamberts et al., 2011). In 13 
addition to the specificity of receptor–G-protein coupling, different selective agonists 14 
for a specific receptor can induce different modes of ligand-receptor interaction, and 15 
the particular activation pattern of G-protein subtypes determines the intrinsic activity 16 
of the agonist for the elicited biological response (Garzón et al., 1998; Sánchez-17 
Blázquez et al., 2001; Valdizán et al., 2010).  18 
One of the best characterised effector systems linked to the opioid receptor signalling 19 
cascade is the adenyl cyclase (AC)/cAMP pathway (Law et al., 2000). Following 20 
receptor activation, opioid drugs exert an inhibitory effect on AC activity through Gi 21 
subunits, resulting in reduced cAMP production (George et al., 2000; Laugwitz et al. 22 
1993; Mostany et al., 2008). The AC/cAMP pathway has long been known to play a 23 
crucial role in the processing of painful stimuli, and studies have demonstrated an 24 
 5 
important role of several AC isoforms in inflammatory and neuropathic pain models, 1 
as well as in opioid-induced analgesia (see Pierre et al., 2009).  2 
Chronic treatment with opioid ligands (agonists and antagonists) as well as other 3 
non-opioid drugs (for example, calcium channel blockers) critically modifies, 4 
quantitatively and qualitatively, opioid receptor signalling. This modification results in 5 
important changes in the pharmacological potency, efficacy and intrinsic activity of 6 
opioid drugs as well as in the quality of the elicited response (Bannister and 7 
Dickenson, 2010; Chang et al., 2007; Dierssen et al., 1990; Gullapalli and Ramarao, 8 
2002; Hurlé et al., 2000; Mostany et al., 2008; Santillán et al., 1998; Vanderah et al., 9 
2001). In this context, the development of functional super-sensitivity to opioid 10 
agonists after long-term exposure to opioid receptor antagonists, such as naloxone, 11 
naltrexone and 6β-naltrexol, is a well-known phenomenon in rodents (Sirohi et al., 12 
2007). For example, we previously reported that the antinociceptive and respiratory 13 
depressant potencies of µ-agonists are enhanced following interruption of long-term 14 
treatment with naltrexone in rats (Díaz et al., 2002). In most of the studies in the 15 
literature, this increased responsiveness to agonists has been correlated with opioid 16 
receptor up-regulation (Díaz et al., 2002; Lesscher et al., 2003; Patel et al., 2003; 17 
Sirohi et al., 2007; Unterwald et al., 1995; Yoburn et al., 1986).  18 
Sustained opioid receptor blockade by naltrexone is among the currently available 19 
treatments for substance abuse and dependence disorders, and the recently 20 
introduced long-acting, sustained-release formulations of naltrexone are considered 21 
to be promising strategies for the treatment of heroin (Krupitsky and Blokhina, 2010), 22 
alcohol (Anton, 2008; Ray et al., 2010) and nicotine (David et al., 2006) dependence. 23 
However, the advantages and disadvantages of these new therapies have not been 24 
systematically analysed. 25 
 6 
The neurochemical adaptations produced by continued opioid antagonist treatment 1 
have scarcely been studied. Here, we further analyse the molecular mechanisms 2 
underlying the increased functional responsiveness to opioid agonists produced by 3 
sustained administration of antagonists in rats. We demonstrate that following long-4 
term treatment with naltrexone, spinal -opioid receptors undergo a transductional 5 
shift from PTX-sensitive Gi/o to PTX-resistant Gz transducer proteins. 6 
Consequently, the inhibitory effect of agonists on the AC/cAMP effector pathway is 7 
enhanced. In addition, the population of constitutively active -receptors in the spinal 8 
cord appears to be increased. These neurochemical changes correlate with the 9 
pharmacological super-sensitivity to the antinociceptive effect of the μ-opioid agonist 10 
sufentanil. 11 
 12 
2. Material and Methods 13 
2.1. Subjects  14 
The experiments were carried out using male Sprague Dawley rats weighing 250–15 
300 g (Charles River, Harlan, Barcelona, Spain). The animals were housed in 16 
sawdust-lined cages in an environmentally controlled animal facility at 22C with a 17 
12:12 h light-dark cycle and food/water provided ad libitum. This study was approved 18 
by the Cantabria University Institutional Laboratory Animal Care and Use Committee 19 
and performed in strict accordance with the “European Directive for the Protection of 20 
Vertebrate Animals Used for Experimental and Other Scientific Purposes” (European 21 
Union Directive #86/606/EEC).  22 
 23 
2.2. Pharmacological treatments 24 
 7 
Diagrams showing the pharmacological treatment schedules are depicted in 1 
supplementary figure S1. Chronic saline (1 l/h) or naltrexone (120 g/h) infusion 2 
was administered using Alzet 2001 osmotic minipumps (Alza Corporation, Palo Alto, 3 
CA, USA) that were implanted subcutaneously under light ether-induced anaesthesia 4 
(figure S1A). These pumps delivered the solutions at a constant rate of 1 µl/h for 7 5 
days. On day 7, the minipumps were removed, and the in vivo (antinociceptive 6 
response to the -opioid receptor agonist sufentanil) or in vitro assays 7 
(autoradiographic, [35S]GTPS binding and adenylyl cyclase studies) were carried out 8 
24 h after withdrawal from a chronic saline or naltrexone treatment.  9 
To interfere with the expression of Gαz proteins, we used a synthetic antisense 10 
oligodeoxynucleotide (ODN) that has previously been characterised (Sanchez-11 
Blazquez et al., 1995; Serres et al., 2000). The sequence was 5′-12 
CGTGATCTCACCCTTGCTCTCTGCCGGGCCAGT-3′. The ODN was 13 
phosphorothioate-modified at the two bases on each end. The sequence of the 14 
missense oligodeoxynucleotide was 5′-CCCTTATTTACTTTCGCC-3′, and it was 15 
phosphorothioate-modified at positions 5′-CC and GC-3′ (Sánchez-Blázquez et al., 16 
1995; Serres et al., 2000). ODNs (5 µg/10 µl) were administered twice 17 
intracerebroventricularly (i.c.v) under light isofluorane-induced anaesthesia with a 24-18 
h interval between administrations (figure S1 B). The Gαz-antisense ODN injection 19 
was performed on days 5 and 7 for the rats receiving chronic naltrexone treatment 20 
(figure S1 C). The rats were challenged with sufentanil 24 h later to test whether the 21 
antinociceptive response elicited by activation of µ-opioid receptors was mediated by 22 
Gαz.  23 
To prevent the activation of Gαi1,2,3 / Gαo proteins, PTX was administered (1 µg/10 µl, 24 
i.c.v.), and the antinociceptive response of sufentanil was tested 48 h later (figure S1 25 
 8 
D). PTX was injected on day 6 to the rats receiving chronic naltrexone treatment 1 
(figure S1 E).  2 
2.3. Evaluation of nociception  3 
The tail-flick test was used to assess the nociceptive threshold. A tail-flick response 4 
was elicited by applying radiant heat to the surface of the tail. The intensity of the 5 
stimulus was adjusted so that control latency was within 3 to 5 sec. A cut-off time of 6 
10 sec was established to avoid permanent injury. Tail-flick latencies were measured 7 
before the drug injection and 30 min after subcutaneous administration of sufentanil 8 
(0.1 or 1 g/kg; figure S1). This drug administration schedule was based on dose-9 
response curves obtained in previous studies (Díaz et al., 2002).  10 
2.4. Autoradiography of -opioid agonist-stimulated [35S]GTPS binding 11 
 [35S]GTPS binding using tissue sections was performed as described previously 12 
(Sim et al., 1996; Mostany et al., 2008). Sections were first preincubated in assay 13 
buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA and 100 mM NaCl; pH 7.4) for 14 
15 min at 25ºC, followed by a second 15-min preincubation in the same assay buffer 15 
containing 2 mM GDP and 10 mU/ml adenosine deaminase. Sections were then 16 
incubated for 2 h at 25ºC in assay buffer containing 1 mM DTT and 0.04 nM 17 
[35S]GTPS. Consecutive sections were used to define basal binding (in the absence 18 
of the opioid agonist), stimulated binding (in the presence of agonist) and non-19 
specific binding (without agonist and in the presence of 10 M GTPS) (Díaz et al., 20 
2002). The -opioid selective agonist DAMGO was used at concentrations ranging 21 
from 10-10 to 10-4 M. After this incubation, slides were rinsed twice in cold Tris buffer 22 
(50 mM Tris-HCl; pH 7.4) for 15 min, dipped in distilled water and dried under an ice-23 
cold air stream.  24 
 9 
Tissue sections incubated with [35S]GTPS were exposed to autoradiographic films 1 
(Kodak-MR films, GE Healthcare, Spain) along with [14C]-radioactive microscales 2 
(GE Healthcare, Spain). In order to generate the autoradiograms, films were 3 
developed following a 48-h ([35S]GTPS binding period. Autoradiographic 4 
densitometry was performed using Scion Image software (Scion Corporation, 5 
Maryland, USA). Autoradiographic values of net agonist-stimulated [35S]GTPS 6 
binding were calculated by subtracting basal binding from agonist-stimulated binding.  7 
2.5. Immunoprecipitation of [35S]GTPS-labelled G subunits 8 
Spinal cord samples were homogenised [1:30 (w/v)] in ice-cold buffer (50 mM Tris-9 
HCl, 250 mM sucrose, 3 mM MgCl2, 1 mM EGTA, and 1 mM DTT; pH 7.4) using a 10 
motor-driven glass Teflon tissue potter (10 strokes, 1500 rpm). The homogenates 11 
were then centrifuged (1500 x g, 5 min, 4°C), and the resulting supernatants were 12 
centrifuged again (14,000 rpm, 15 min, 4°C). Resuspended pellets (500 g 13 
protein/ml/assay) were incubated with 20 nM [35S]GTPS and 10 M DAMGO in a 14 
final volume of 100 l for 30 min at 30ºC. Non-specific binding was determined in the 15 
presence of 10 M of GTPS. Membrane suspensions were then solubilised on ice 16 
with in a solution containing 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS, 2.5 17 
mM CHAPS, 0.1 mM phenylmethylsulfonylfluoride, 0.01 M aprotinin, 1 µg/ml 18 
leupeptin, 1 µg/ml pestatin, 1 µl/ml antipain, and 10 µg/ml chymostatin for 30 min. 19 
Solubilised membranes were incubated for 3 h at room temperature with 15 l of 20 
specific rabbit anti-Go, anti-Gi1-2-3, and anti-Gz antibodies immobilised to 21 
superparamagnetic Dynabeads® Protein A (overnight, 4ºC). After three washes with 22 
1 ml of PBS, the beads were pelleted, and the bound radioactivity was counted in 4 23 
ml of Ecolite scintillation cocktail. Antibody specificity was confirmed in our 24 
experimental conditions by western blot analysis, as previously described (Mato et 25 
 10 
al., 2009). The amount of coupling of -opioid receptors to the diverse G protein 1 
subunits induced by DAMGO (10-4 M) was expressed as percentage over the basal 2 
values in the absence of the agonist (100%).  3 
2.6. Cyclic AMP assays 4 
AC assays were performed using spinal cord samples as described previously 5 
(Mostany et al., 2008). Samples were homogenised (1:60 weight/volume dilution) 6 
with a Teflon/glass grinder (10 strokes, 800 r.p.m.) in an ice-cold homogenisation 7 
buffer (20 mM Tris-HCl, 1 mM EGTA, 5 mM EDTA, 5 mM DTT, 25 M leupeptin and 8 
300 mM sucrose; pH 7.4). The homogenates were centrifuged at 1,500 x g (5 min at 9 
4ºC), and the resulting supernatants were centrifuged at 13,000 x g (15 min at 4ºC). 10 
The pellets were resuspended (120 g protein/ml) in assay buffer (80 mM Tris-HCl, 11 
0.2 mM EGTA, 1 mM EDTA, 2 mM MgCl2, 100 mM NaCl, 60 mM sucrose, 1 mM 12 
DTT, 10 M GTP, 0.5 mM IBMX, 5 mM phosphocreatine, 50 U/ml creatine 13 
phosphokinase, and 5 U/ml myokinase; pH 7.4) without (basal AC activity) or with 10 14 
μM forskolin (FK) (FK-stimulated cAMP accumulation). Opioid receptor-mediated 15 
inhibition of FK-stimulated cAMP accumulation was determined using different 16 
concentrations of the agonist DAMGO (10-9 to 10-4 M). To test the effect of PTX on 17 
DAMGO-induced inhibition of FK-stimulated cAMP accumulation, samples were 18 
preincubated for 30 min with or without PTX (1 μg/ml) in buffer (25 mM Tris-HCl 19 
buffer containing 0.05% SDS, 10 mM DTT, 1 mM EDTA, 2.5 μM NAD, and 10 mM 20 
thymidine; pH 7.4, 30ºC). The inverse agonism of naltrexone (10-7 to 10-3 M) was 21 
analysed by measuring cAMP accumulation in the absence of NaCl and FK (Mato et 22 
al., 2002). The effects of selective opioid antagonists (, β-funaltrexamine; , 23 
naltrindole; and κ, nor-binaltorphimine) added to the media at a concentration of 10-4 24 
M were evaluated. 25 
 11 
Membranes under the different experimental protocols were preincubated for 5 min 1 
at 37ºC, then ATP was added to a final concentration of 200 M and the mixture was 2 
incubated for 10 min at 37ºC. The reaction was stopped by boiling for 5 min, and the 3 
cAMP concentration was determined in a 50 l sample of the supernatant using a 4 
commercial kit (Cyclic AMP 3H assay system, Amersham Biosciences, Barcelona, 5 
Spain). Each cAMP assay was performed in triplicate, and the results are expressed 6 
as pmol cAMP/min/mg protein.  7 
2.7. Drugs and chemicals 8 
Sufentanil was kindly provided by Janssen Cylag, S.A. (Madrid, Spain). DAMGO, 9 
naltrexone and FK were purchased from Sigma (Madrid, Spain). The selective 10 
antagonists of -opioid receptors (β-funaltrexamine), -opioid receptors (naltrindole) 11 
and -opioid receptors (nor-binaltorphimine) were obtained from Tocris Bioscience 12 
(Biogen S.L., Madrid, Spain). [35S]GTPS (1250 Ci/mmol) was purchased from Perkin 13 
Elmer (Madrid, Spain). PTX was purchased from Calbiochem (Roche Diagnostics, 14 
Barcelona, Spain). The ODNs were synthesised by Sigma-Genosys Ltd. (Cambridge, 15 
UK). Selective rabbit polyclonal antibodies against Go, Gi1,2,3, and Gz subunits 16 
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 17 
Representative immunoblots showing the specificity of the antibodies are shown in 18 
supplementary figure S2. 19 
2.8. Data analysis 20 
Data analysis was performed using the GraphPad Prism statistical software package 21 
(GraphPad Software, Inc., San Diego, CA, USA). Data from the [35S]GTPS binding 22 
and AC assays were fitted to sigmoidal concentration-response curves to determine 23 
potency (EC50 and IC50, respectively) and theoretical maximal effect (Emax and Imax, 24 
respectively). The EC50 and IC50 values were normalised as -logEC50 (pEC50) and -25 
 12 
logIC50 (pIC50) for statistical comparison. Data represent the mean  standard error of 1 
the mean (S.E.M.). Statistical analysis was performed using Student’s t-tests and 2 
one-way ANOVA followed by the Newman-Keuls post-hoc test when appropriate. A 3 
p<0.05 was considered to be statistically significant.  4 
 5 
3. Results 6 
3.1. Chronic naltrexone treatment increases DAMGO-induced [35S]GTPS 7 
binding  8 
Basal and agonist-induced -opioid receptor activation of G-proteins was determined 9 
by [35S]GTPS binding using spinal cord sections. The basal level of [35S]GTPS 10 
binding was not different between groups. However, animals chronically treated with 11 
naltrexone exhibited a significant increase in -opioid receptor-mediated stimulation 12 
of [35S]GTPS binding. The maximal stimulatory effect induced by the selective -13 
opioid agonist DAMGO on spinal cord [35S]GTPS binding was significantly enhanced 14 
in comparison with saline-treated rats, as indicated by the Emax values determined 15 
from the concentration-response curves. In contrast, the potency between groups 16 
was not different (table 1; figure 1). These data suggest that the -opioid receptor 17 
coupling to G proteins was increased following chronic naltrexone treatment.  18 
We also confirmed that chronic naltrexone treatment increased the specific binding of 19 
3H-DAMGO to -opioid receptors (Díaz et al., 2002;), consistent with the reported up-20 
regulation of µ-opioid receptors induced by chronic naltrexone treatment (Yoburn et 21 
al., 1986; 1995; Unterwald et al., 1995; Lesscher et al., 2003; Patel et al., 2003; 22 
Sirohi et al., 2007).  23 
 13 
3.2. Chronic naltrexone treatment causes potentiation of -opioid agonist-1 
induced inhibition of cAMP accumulation through a mechanism involving PTX-2 
resistant G proteins 3 
Basal AC activity and the ability of the AC activator FK (10 M) to increase cAMP 4 
levels were not altered following long-term administration of naltrexone in comparison 5 
with saline-treated animals (table 1). In control rats, incubation of the spinal cord 6 
membranes with increasing concentrations (10-9 to 10-4 M) of the selective -opioid 7 
agonist DAMGO produced a concentration-dependent inhibition of FK-stimulated 8 
cAMP accumulation. Following long-term treatment with naltrexone, the maximal 9 
ability of DAMGO to inhibit FK-induced cAMP accumulation was significantly 10 
enhanced with no change in potency (table 1). PTX causes the ADP-ribosylation and 11 
inactivation of Gi/o proteins, with the exception of Gz (Casey et al., 1990). The 12 
presence of PTX in the medium did not modify either basal or FK-stimulated cAMP 13 
accumulation (table 1, figure 2). However, in saline-treated animals, the maximal 14 
inhibitory effect of DAMGO was almost completely prevented by PTX pretreatment, 15 
suggesting the involvement of Gi/o proteins. On the contrary, in the group of animals 16 
chronically treated with naltrexone, PTX did not antagonise the maximal inhibitory 17 
effect of DAMGO on FK-induced cAMP accumulation, suggesting the involvement of 18 
Gz proteins (figure 2). 19 
3.3. Chronic naltrexone treatment increases -opioid receptor coupling to Gz 20 
protein subunits 21 
To further assess the existence of specific changes in the coupling of -opioid 22 
receptors to the PTX-resistant Gz subunits, we performed immunoprecipitation of 23 
DAMGO-activated [35S]GTPS-labelled G protein subunits.  24 
 14 
In spinal cord homogenates from animals treated with chronic naltrexone, the 1 
coupling of -opioid receptors to G proteins was significantly increased in 2 
comparison with saline-treated animals (183.0 ± 13.3% vs. 140.1 ± 9.0% of basal 3 
binding; p<0.05). Western blot analysis of spinal cord samples revealed no change in 4 
the expression of any G subunit after chronic naltrexone treatment (see methods 5 
and figure S3 in the supplementary information). However, as shown in figure 3, the 6 
DAMGO-induced activation of Gz subunits was significantly increased in chronic 7 
naltrexone-treated animals in comparison with the saline group (301.6 ± 39.9% vs. 8 
170.7 ± 10.2% of basal binding; p<0.05). Significant differences in the coupling with 9 
Go (194.4 ± 7.7% vs. 172.6 ± 5.8%) and Gi1-2-3 (178.9 ± 7.3% vs. 160.6 ± 9.6%) 10 
were not observed between naltrexone- and saline-treated animals. 11 
3.4. Potentiation of -opioid antinociception following withdrawal from chronic 12 
naltrexone involves Gαz proteins 13 
The functional relevance of the transduction switch from Gαi/o to Gαz proteins was 14 
assessed by analysing the consequences of PTX or Gαz-antisense ODN 15 
pretreatment on the antinociceptive response to sufentanil. Under baseline conditions 16 
(Fig. 4A), sufentanil, acutely administered at the dose of 1 µg/kg (n=10), produced an 17 
antinociceptive response that almost reached the MPE; this effect was prevented by 18 
PTX (1 µg/10 µl, i.c.v.) administered 48 h beforehand (n=5). In contrast, pretreatment 19 
with Gαz-antisense ODN (5 µg/10 µl, two i.c.v. injections on alternate days; n=5) did 20 
not significantly modify the effect of sufentanil. Neither saline nor missense ODN 21 
administered i.c.v. modified the tail-flick basal response or sufentanil-induced 22 
antinociception. These results indicate that sufentanil-induced antinociception in 23 
naïve animals is dependent on the interaction of -opioid receptors with PTX-24 
sensitive Gαi/o transducer proteins rather than PTX-insensitive Gαz subunits.  25 
 15 
In the rats that received the chronic naltrexone treatment (figure 4B), the 1 
antinociceptive response of sufentanil (0.1 µg/kg; n = 5) was significantly potentiated, 2 
confirming “in vivo” the development of functional super-sensitivity to the 3 
antinociceptive effect of sufentanil. PTX injected on the 6th day of chronic naltrexone 4 
infusion did not prevent the development of opioid super-sensitivity. On the other 5 
hand, Gαz-antisense ODN injected i.c.v. on days 5 and 7 of the chronic naltrexone 6 
infusion completely prevented the development of super-sensitivity to the 7 
antinociceptive response elicited by sufentanil. The reduction in the expression levels 8 
of Gαz–proteins in the dorsal horn of the spinal cord induced by Gαz-antisense ODN 9 
treatment was confirmed by western blotting experiments (Figure 5). Overall, these 10 
results indicate that following withdrawal from chronic naltrexone, the antinociceptive 11 
response mediated by µ-opioid receptor activation involved Gαz-transducer proteins.  12 
3.5. Chronic naltrexone treatment increases the constitutive activity of -opioid 13 
receptors 14 
Incubation of spinal cord membranes from saline-treated rats with increasing 15 
concentrations of naltrexone induced a concentration-dependent increase in the 16 
levels of cAMP (Emax = 29.1 ± 0.7 pmol/min/mg; pEC50 = 4.2 ± 0.3). This inverse-17 
agonist action of naltrexone was potentiated after chronic administration of 18 
naltrexone because the maximal cAMP production appeared significantly enhanced 19 
(Emax= 35.3  0.8, p < 0.01 vs. saline-treated group; pEC50 = 4.1  0.2; p= NS), 20 
indicating the existence of constitutively active opioid receptors that uncovered the 21 
inverse-agonist effect of naltrexone (figure 6A).  22 
To determine the subtype of opioid receptor that exhibited constitutive activity, the 23 
effect of naltrexone on cAMP levels was evaluated in the presence of selective 24 
antagonists to - (β-funaltrexamine), - (naltrindole) and - (nor-binaltorphimine) 25 
 16 
receptors at a concentration of 10-4 M. The effect of each antagonist alone was 1 
examined in parallel, and only nor-binaltrophimine increased cAMP levels (data not 2 
shown), confirming its reported inverse agonism (Wang et al., 2007). As shown in 3 
figure 6B, β-funaltrexamine antagonised the naltrexone-induced cAMP increase both 4 
in the saline-treated group (109.1  2.9% vs. 121.1  5.4% in the absence of β-5 
funaltrexamine; p<0.05) and in the chronic naltrexone-treated group (114.4  0.4% 6 
vs. 147.2  2.2% in the absence of β-funaltrexamine; p<0.01). Naltrindole (10-4M) did 7 
not modify the naltrexone-induced cAMP increase in any group. The same 8 
concentration of naltrindole antagonised the binding of [35S]GTPγS induced by the δ-9 
specific agonist DSLET (Figure S4). Nor-binaltrophimine not only was unable to 10 
antagonise but also increased naltrexone-induced cAMP accumulation in both the 11 
saline group (142.2  2.1%; p<0.01 vs. the effect of naltrexone alone) and the chronic 12 
naltrexone group (165.3  10.1%; p<0.05 vs. the effect of naltrexone alone). 13 
Furthermore, immunoprecipitation assays that were carried out using spinal cord 14 
samples from saline and chronic naltrexone-treated animals demonstrated the 15 
absence of naltrexone-induced coupling with Gs (104  8.1%). Overall, our data 16 
support the interaction of naltrexone with constitutively active µ-opioid receptors. 17 
 18 
4. Discussion 19 
Functional super-sensitivity to opioid agonists induced by sustained exposure to 20 
antagonists is a well-known phenomenon in rodents. Most studies addressing the 21 
underlying mechanisms have focused on the up-regulation of opioid receptors in the 22 
CNS subsequent to blockade (Díaz et al., 2002; Lesscher et al., 2003; Patel et al., 23 
2003; Sirohi et al., 2007; Unterwald et al., 1995; Yoburn et al., 1986; 1995). 24 
Treatment with naltrexone clearly induces the up-regulation of - and, to a lesser 25 
 17 
extent, - and -opioid receptors throughout the brain, with differences in the per cent 1 
change across various brain regions (Lesscher et al., 2003; Yoburn et al., 1995). 2 
Furthermore, the increase in the maximal stimulatory effect of DAMGO on the spinal 3 
cord binding of [35S]GTPS indicates the existence of enhanced coupling between -4 
opioid receptors and their cognate G-proteins.  5 
Regarding intracellular effectors, one of the best-characterised signalling cascades 6 
linked to opioid receptor activation is the AC/cAMP pathway (Law et al., 2000). This 7 
pathway has long been known to play a crucial role in processing nociception. In 8 
addition to opioids, other pharmacological agents with analgesic properties exert an 9 
inhibitory influence on this pathway (Pierre et al., 2009). In agreement with previous 10 
reports (George et al., 2000; Laugwitz et al. 1993; Mostany et al. 2008), we observed 11 
that PTX-sensitive Gi subunits were the preferential transducers linking µ-opioid 12 
receptor activation to the AC/cAMP pathway in naive animals. Following chronic 13 
naltrexone treatment, the inhibitory effect of DAMGO on the AC/cAMP pathway was 14 
significantly potentiated. However, under these experimental conditions, the effect 15 
was not prevented by PTX, in contrast to the saline-treated group. Thus, our data 16 
indicate that following chronic treatment with antagonists, µ-opioid receptors 17 
underwent a shift in the transduction of their signal, showing a higher efficiency of 18 
interaction with PTX-resistant over PTX-sensitive Gα proteins. A likely transducer 19 
candidate is Gz, which is the only G subunit resistant to PTX (Casey et al., 1990) 20 
that inhibits AC (Kozasa and Gilman, 1995; Mostany et al., 2008). Consistent with 21 
this assumption, the immunoprecipitation data indicated that the coupling of -opioid 22 
receptors to Gz subunits was augmented following withdrawal from chronic 23 
naltrexone, whereas the coupling to Go and Gi1-2-3, subunits remained similar to 24 
that observed in saline-treated rats.  25 
 18 
Although the present study provides no information about the mechanisms that could 1 
explain why the switch from Gi to Gz transducer proteins resulted in an 2 
enhancement of the opioid inhibitory effect on the AC/cAMP effector pathway, 3 
several observations led us to propose some putative mechanisms for such a 4 
phenomenon. First, the rate of GzGTP hydrolysis is as much as 200-fold slower 5 
than that determined for other G protein α subunits. This extremely slow rate of GTP 6 
hydrolysis would then result in a long-lasting signal (Casey et al., 1990; Jeong and 7 
Ikeda 1998). Second, the inhibitory G subunits differ in their specificity for individual 8 
AC isoforms. For example, it has been suggested that the relatively high affinity of 9 
Gz for AC type V, together with its slow GTPase activity, might account for its 10 
capacity to induce strong AC inhibition in cultured cells (Ammer and Christ, 2002). 11 
Finally, Gz may be difficult to switch off after receptor activation unless external 12 
factors, such as RGS-Rz proteins, accelerate the rate of GzGTP hydrolysis. In 13 
particular, RGSZ2 plays an important role in controlling µ-opioid signalling induced by 14 
Gz transducer proteins (Garzón et al., 2005). Thus, it may be feasible that, following 15 
chronic naltrexone treatment, an inadequate control of Gz activity may lead to 16 
strong inhibition of the AC/cAMP pathway.  17 
The functional relevance of the particular transducer protein linking µ-opioid receptor 18 
activation to the AC/cAMP signalling pathway is strengthened by our data that 19 
demonstrate the close relationship between agonist-activated signalling “in vitro” and 20 
agonist-induced pharmacological effects “in vivo”. Thus, as observed in the AC 21 
assay, sufentanil-induced antinociception in naive rats was prevented by PTX but not 22 
by Gαz antisense ODN, indicating the involvement of Gαi/o transducer proteins. In 23 
contrast, following withdrawal from chronic naltrexone treatment, the switch from 24 
Gαi/o to Gαz proteins appeared to be responsible for the enhanced antinociceptive 25 
 19 
response to µ-opioid agonists because sufentanil-induced antinociception was 1 
prevented by Gαz antisense ODN but not by PTX pretreatment. 2 
Aside from Gα transducer proteins and the AC/cAMP pathway, chronic treatment 3 
with naltrexone could have additional consequences on other elements linked to µ-4 
opioid receptor signalling that were not analysed in this study. In this regard, voltage-5 
gated Ca2+ channels and G protein-coupled inwardly rectifying K+ channels are 6 
fundamental determinants of opioid-induced antinociception (Law et al., 2000; Heinke 7 
et al., 2011), whose modulation by Gαz has been described in several reports (see 8 
Ho and Wong, 2001). Moreover, Gβγ-subunits broadly regulate Kir3 channels, 9 
voltage-gated Ca2+ channels, phospholipase Cβ, and several isoforms of AC, among 10 
other effectors (Dupré et al., 2008).  11 
In addition to chronic naltrexone treatment, a number of pharmacological 12 
interventions induce analogous signalling plasticity on -opioid receptors with similar 13 
functional consequences. In this regard, we previously reported that 7 days of 14 
combined treatment with nimodipine (L-type calcium channel blocker) and sufentanil 15 
prevents the development of tolerance and strongly enhances the antinociception in 16 
rats (Dierssen et al., 1990; Hurlé et al., 2000; Mostany et al., 2008). The underlying 17 
mechanism involved efficient inhibition of cAMP production associated with a change 18 
in -opioid receptor–preferred G-protein coupling from PTX-sensitive Gi to PTX-19 
resistant Gz subunits (Mostany et al., 2008). Changes in sensitivity to agonists have 20 
also been reported to occur upon heterodimerisation of opioid receptors. Studies 21 
using cultured cells provide evidence that -selective antagonists enhance -opioid 22 
receptor signalling through a mechanism involving the formation of – hetero-23 
oligomeric signalling units and a subsequent switch in opioid-receptor preference for 24 
Gz over Gi subunits, which are preferentially activated by individually expressed - 25 
 20 
and -receptors (Fan et al., 2005; George et al., 2000; Hasbi et al., 2007). 1 
Experiments in vivo demonstrate that this change in opioid-receptor transduction 2 
leads to increased -receptor binding and signalling activity and to an enhancement 3 
of morphine antinociceptive potency in mice (Abul-Husn et al., 2007; Gomes et al., 4 
2004). Taken together, these findings suggest that conditions favouring the coupling 5 
of -opioid receptors to Gz-protein subunits would increase agonist-induced 6 
AC/cAMP signalling pathways, leading to an enhancement of the pharmacological 7 
responses. 8 
Another relevant adaptive response prompted by sustained opioid receptor blockade 9 
arises from the observation that the inverse agonist effect of naltrexone on the AC 10 
activity was significantly potentiated. Opioid receptors, similar to other G-protein 11 
coupled receptors, may exhibit spontaneous constitutive activity even in the absence 12 
of agonists (Sadée et al., 2005). It has also been reported that antagonists, such as 13 
naloxone and naltrexone, display inverse agonist activity when the population of 14 
constitutively active opioid receptors increases, which is typically more prominent 15 
following chronic treatment with opioid agonists (Liu and Prather, 2001; Wang et al., 16 
2001; Wang et al., 2007). On the other hand, the in vitro inverse agonist activity of 17 
naltrexone and other putative -inverse agonists has been questioned by Divin et al. 18 
2009. These authors observed that, under chronic treatment and the subsequent 19 
rapid removal of opioid agonist, cells expressing -opioid receptors exhibit an 20 
enhanced cAMP accumulation not linked to the formation of constitutively active -21 
opioid receptors. 22 
Our present results demonstrate for the first time in native tissue that the inverse 23 
agonism of naltrexone, reflected by cAMP accumulation, occurs after sustained 24 
treatment with opioid antagonists. Furthermore, our findings support the fact that the 25 
 21 
stimulatory effect of naltrexone on cAMP accumulation was mediated by µ-opioid 1 
receptors. In addition, immunoprecipitation assays indicated the lack of involvement 2 
of Gs subunits in this effect, demonstrating that naltrexone could not induce the 3 
coupling of -opioid receptors to these stimulatory subunits. Considering that 4 
receptor over-expression leads to a proportional increase in the number of 5 
spontaneously active receptors (see Leurs et al., 1998), constitutive signalling may 6 
be enhanced after withdrawal from chronic naltrexone treatment as a consequence 7 
of -opioid receptor up-regulation. However, sensitisation of the receptor to the 8 
effects of inverse agonists cannot be ruled out (Divin et al., 2008; Liu and Prather, 9 
2001; Wang et al., 2007).  10 
Interestingly, we observed a potentiation of naltrexone inverse agonism by the -11 
opioid antagonist nor-binaltorphimine. In this regard, Wang et al. (2007) 12 
demonstrated that naltrexone has inverse agonist properties at - but not at - and -13 
opioid receptors in cultured cells over-expressing opioid receptors. In this study and 14 
in our study (data not shown), nor-binaltorphimine exhibited inverse agonist activity at 15 
-receptors. Thus, such an increase in cAMP accumulation induced by naltrexone in 16 
the presence of nor-binaltorphimine may be explained by the sum of their respective 17 
inverse agonist effects on - and -receptors. 18 
5. Conclusions 19 
Following long-term treatment with naltrexone, -receptors in the spinal cord 20 
experienced a transduction shift from PTX-sensitive Go and Gi1-2-3 proteins to PTX-21 
resistant Gz proteins. As a result, the inhibitory effect of the -agonist DAMGO on 22 
the AC/cAMP effector pathway was enhanced. In addition, constitutively active -23 
opioid receptor expression, and possibly -opioid receptor expression, in the spinal 24 
cord appeared to be increased. The functional consequence of these neurochemical 25 
 22 
changes is the development of pharmacological super-sensitivity to the 1 
antinociceptive effect of -receptor agonists, such as sufentanil. Such changes in 2 
opioid receptor signalling activity can be a double-edged sword. On the one hand, 3 
they may have potential applicability to the optimisation of the analgesic effects of 4 
opioid drugs for the control of pain. On the other hand, they represent an important 5 
homeostatic dysregulation of the endogenous opioid system that might account for 6 
undesirable paradoxical pharmacological effects in patients chronically treated with 7 
certain opioid antagonists.  8 
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Figure legends  1 
 2 
Figure 1. Effect of chronic naltrexone treatment on DAMGO-induced [35S]GTPS 3 
binding. Left: Concentration–response curves of DAMGO-stimulated [35S]GTPS 4 
binding using spinal cord sections from animals chronically treated for 7 days with 5 
saline and naltrexone (120 μg/h). Values (mean ± S.E.M.) represent specific 6 
[35S]GTPS binding in nCi/mg tissue. Right: Representative autoradiographic 7 
illustrations showing basal (A and B) and 10 μM DAMGO-stimulated (C and D) 8 
[35S]GTPS binding in spinal cord sections from animals chronically treated for 7 days 9 
with saline (A and C) and naltrexone (B and D). Note the enhanced response to 10 
DAMGO following withdrawal from chronic naltrexone in the outer layers of the dorsal 11 
horn (laminae I and II). Abbreviations: DH, dorsal horn; VH, ventral horn. 12 
 13 
Figure 2. Effect of pertussis toxin (PTX) on DAMGO-induced inhibition of FK-14 
stimulated cAMP accumulation in spinal cord homogenates from rats chronically 15 
treated with saline or naltrexone. Data represent the mean ± S.E.M. PTX prevented 16 
opioid-induced inhibition of FK-stimulated cAMP accumulation in spinal cord 17 
homogenates from saline- but not naltrexone-treated rats (**p < 0.01 and ***p < 0.01 18 
vs. FK). 19 
 20 
Figure 3. Selective [35S]GTPS labelling of Go, G1,2,3 and Gz protein subunits 21 
activated by the -opioid agonist DAMGO in the spinal cord homogenates from rats 22 
chronically treated with saline or naltrexone. G protein subunits were isolated using 23 
antibodies against each subtype immobilised to superparamagnetic Dynabeads. Data 24 
represent the mean ± S.E.M. of the per cent bound relative to basal binding (100%) for 25 
 32 
each specific G-protein subunit (*p < 0.05 vs. saline (Newman-Keuls post-ANOVA)). 1 
Note the selective increase of [35S]GTPS labelling of Gz following chronic 2 
administration of naltrexone. 3 
 4 
Figure 4. Antinociceptive effect of sufentanil in the tail-flick test.  Naive rats (A) and 5 
rats chronically treated with naltrexone (B) were challenged with sufentanil after i.c.v 6 
pretreatment with saline, pertussis toxin (PTX; 1 µg/10 µl), Gαz antisense 7 
oligodeoxynucleotide (ODN; 2 x 5 µg/10 µl) or missense ODN (2 x 5 µg/10 µl). Data 8 
represent the mean ± S.E.M. of the per cent antinociception relative to the maximal 9 
possible effect (100%) (**p < 0.01 vs. saline; ***p < 0.001 vs. baseline; ##p < 0.001 10 
vs. saline (Newman-Keuls post-ANOVA). 11 
 12 
Figure 5. Effect of Gαz antisense oligodeoxynucleotide on the levels of Gαz proteins 13 
in the dorsal horn of the spinal cord. Representative immunoblots and integrated 14 
optical density (OD) of the bands show a down-regulation of Gαz proteins following 15 
antisense ODN, both in saline and naltrexone (NTX) treated rats. Data represent the 16 
mean ± S.E.M. from four animals per group of the per cent OD relative to missense 17 
ODN. (*p < 0.05 vs missense ODN; Newman-Keuls post-ANOVA). 18 
 19 
Figure 6. Naltrexone-induced cAMP accumulation in spinal cord homogenates from 20 
animals chronically treated for 7 days with saline or naltrexone (120 μg/h) and 21 
selective opioid antagonists. (A): Concentration–response curves of naltrexone-22 
induced cAMP accumulation (pmol/min/mg protein); (B) Antagonism of naltrexone-23 
induced cAMP accumulation by the selective antagonists of - (β-funaltrexamine), -24 
(naltrindole) and - (nor-binaltrophimine) receptors (percentage with respect to the 25 
 33 
basal value, 100%). Data represent the mean ± S.E.M. Note the increase in the 1 
naltrexone inverse agonist effect following chronic administration of the opioid 2 
antagonist, which is completely abolished by treatment with the selective -opioid 3 
antagonist β-funaltrexamine, supporting the interaction of naltrexone with 4 
constitutively active µ-opioid receptors (*p < 0.05, **p < 0.01 and ***p < 0.001 vs. 5 
basal value of cAMP level (Newman-Keuls post-ANOVA); +p < 0.05 and ++p < 0.01 6 
vs. naltrexone (Newman-Keuls post-ANOVA). 7 
  
Table 1 
Effect of chronic administration of naltrexone (120 g/hr, 7 days) in -opioid 
receptor density and functionality, and on adenylyl cyclase (AC) activity  
Type of assay Saline Chronic naltrexone 
Autoradiographic density of [3H]-DAMGO 
binding (fmol/mg tissue) 
 
42.424.15 
 
75.427.52**   
[35S]GTPS binding autoradiography   
   Basal binding (nCi/mg tissue) 250. 2240.12 278. 2324.12 
DAMGO-stimulated binding   
      Emax (nCi/mg tissue) 
      pEC50 (-log EC50) 
 
538.2048.01 
5.890.35 
 
736.539.75** 
5.860.14 
Adenylyl cyclase (AC) activity 
  
Basal AC activity (pmol/min/mg protein) 21.303.90 27.503.79 
Forskolin-induced cAMP accumulation 
(pmol/min/mg protein) 
DAMGO inhibition          
 Imax (pmol/min/mg protein)  
    pIC50 (-log IC50) 
599.6125.34 
 
462,42±14.28 
6.480.47 
553.9843.79 
 
389.4429,36* 
6.880.16 
 
Emax represents DAMGO-induced maximal stimulation of [
35
S]GTPS binding; Imax represents 
DAMGO-induced maximal inhibition of forskolin-induced cAMP-accumulation. Values are given 
as meansS.E.M. of data from 6-7 animals/group. *p< 0.05 and **p< 0.01 vs saline-treated 
group (un-paired t test).  
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Highlights 
1. Chronic treatment with opioid antagonists increases agonist-mediated 
antinociception  
2. We examine spinal cord changes in -opioid receptor signalling underlying 
this effect  
3. Opioid receptor-coupling to G-proteins and inhibition of cAMP pathway are 
enhanced  
4. -opioid receptors experience a transduction shift from Gi/o to Gz proteins  
5. The inverse agonist effect of naltrexone on cAMP accumulation is enhanced  
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